subtypes in nsclc: braf and ret
Published 8 years ago • 305 plays • Length 5:45Download video MP4
Download video MP3
Similar videos
-
3:10
targeting braf in nsclc
-
1:51
dr. bauman on treatments for patients with braf-mutant nsclc
-
4:58
treatment of nsclc with ret fusions
-
4:16
combination therapy in braf-mutant nsclc
-
7:36
braf/mek efficacy in braf-mutant nsclc
-
5:55
patient selection in braf-mutant nsclc
-
3:16
nsclc: the braf/mek combination safety profile
-
3:43
understanding the braf-mutated population in nsclc
-
1:58
unmet needs in braf nsclc
-
9:16
changing treatment paradigm for braf-mutant nsclc
-
6:43
considering targeted agents in braf-mutant nsclc
-
3:49
dual targeting of brak and mek in nsclc
-
1:38
more focus is needed on subtypes of lung cancer that do not have fda-approved targeted therapies
-
1:07
dr. subbiah on the fda approval of pralsetinib in ret nsclc
-
1:19
how do doctors treat lung cancer with braf mutations?
-
4:59
outcomes with chemotherapy in braf-mutant nsclc
-
8:42
what is the bac subtype of lung cancer and why does it matter?
-
6:30
testing for kras mutations in nsclc
-
14:45
potential and progress in targeting less common markers: her2, braf, kras, met, trk, and ret